国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
4期
455-458
,共4页
促性腺激素类似物%生长激素%特发性中枢性性早熟%疗效
促性腺激素類似物%生長激素%特髮性中樞性性早熟%療效
촉성선격소유사물%생장격소%특발성중추성성조숙%료효
Gonadotropin-releasing hormone analog%Growth hormone%Idiopathic central precocious puberty%Curative effect
目的 观察促性腺激素类似物联合生长激素治疗女性初潮后特发性中枢性性早熟的临床疗效,为本病的临床治疗提供参考.方法 选取女性初潮后特发性中枢性性早熟患者32例.采用促性腺激素类似物联合生长激素进行治疗,治疗6个月后,观察患者治疗前、后的骨龄、乳房Tanner分期、身高、身高标准差分值、预测成人身高、生长速率、子宫和卵巢容积的变化情况.同时对比患者治疗前、后黄体生成素、卵泡刺激素的变化情况.结果 患者治疗前、后的实际年龄、骨龄、实际年龄和骨龄比值、乳房Tanner分期、HtSDSCA的对比,差异没有统计学意义(P＞0.05).治疗后,患者的身高、预测成人身高、生长速率均显著高于治疗前,而HtSDSBA则显著低于治疗前(P＜0.05).治疗后,患者的子宫容积为(1.37±0.47) cm3,卵巢容积(1.12±0.46) cm3,均显著低于治疗前(P＜0.05).治疗后,黄体生成素峰值为(1.57±0.67) U/L,卵泡刺激素峰值为(3.52±0.81)mU/ml,均显著低于治疗前(P＜0.05).结论 促性腺激素类似物联合生长激素可提高女性初潮后特发性中枢性性早熟的临床治疗效果,改善患者的预测成人最终身高,值得在临床上推广应用.
目的 觀察促性腺激素類似物聯閤生長激素治療女性初潮後特髮性中樞性性早熟的臨床療效,為本病的臨床治療提供參攷.方法 選取女性初潮後特髮性中樞性性早熟患者32例.採用促性腺激素類似物聯閤生長激素進行治療,治療6箇月後,觀察患者治療前、後的骨齡、乳房Tanner分期、身高、身高標準差分值、預測成人身高、生長速率、子宮和卵巢容積的變化情況.同時對比患者治療前、後黃體生成素、卵泡刺激素的變化情況.結果 患者治療前、後的實際年齡、骨齡、實際年齡和骨齡比值、乳房Tanner分期、HtSDSCA的對比,差異沒有統計學意義(P＞0.05).治療後,患者的身高、預測成人身高、生長速率均顯著高于治療前,而HtSDSBA則顯著低于治療前(P＜0.05).治療後,患者的子宮容積為(1.37±0.47) cm3,卵巢容積(1.12±0.46) cm3,均顯著低于治療前(P＜0.05).治療後,黃體生成素峰值為(1.57±0.67) U/L,卵泡刺激素峰值為(3.52±0.81)mU/ml,均顯著低于治療前(P＜0.05).結論 促性腺激素類似物聯閤生長激素可提高女性初潮後特髮性中樞性性早熟的臨床治療效果,改善患者的預測成人最終身高,值得在臨床上推廣應用.
목적 관찰촉성선격소유사물연합생장격소치료녀성초조후특발성중추성성조숙적림상료효,위본병적림상치료제공삼고.방법 선취녀성초조후특발성중추성성조숙환자32례.채용촉성선격소유사물연합생장격소진행치료,치료6개월후,관찰환자치료전、후적골령、유방Tanner분기、신고、신고표준차분치、예측성인신고、생장속솔、자궁화란소용적적변화정황.동시대비환자치료전、후황체생성소、란포자격소적변화정황.결과 환자치료전、후적실제년령、골령、실제년령화골령비치、유방Tanner분기、HtSDSCA적대비,차이몰유통계학의의(P＞0.05).치료후,환자적신고、예측성인신고、생장속솔균현저고우치료전,이HtSDSBA칙현저저우치료전(P＜0.05).치료후,환자적자궁용적위(1.37±0.47) cm3,란소용적(1.12±0.46) cm3,균현저저우치료전(P＜0.05).치료후,황체생성소봉치위(1.57±0.67) U/L,란포자격소봉치위(3.52±0.81)mU/ml,균현저저우치료전(P＜0.05).결론 촉성선격소유사물연합생장격소가제고녀성초조후특발성중추성성조숙적림상치료효과,개선환자적예측성인최종신고,치득재림상상추엄응용.
Objectives To observe the clinical effect of gonadotropin-releasing hormone analog in combination with growth hormone in the treatment of girls with post-menarche idiopathic central precocious puberty and provide some references for the clinical treatment of the disease.Methods 32 girls with postmenarche idiopathic central precocious puberty were selected from our hospital.They were treated with gonadotropin-releasing hormone analog and growth hormone for 6 months.The bone age,breast tanner staging,height,standard deviation scores of height,predicted adult height changes,growth rate,ovarian and uterine volume were observed before and after the treatment.At the same time,luteinizing hormone and follicle stimulating hormone were compared.Results The actual age,bone age,the ratio of actual age to bone age,Tanner stage and HtSDScA showed no significant differences before and after the treatment (P ＞ 0.05).After the treatment,the height,predicted adult height,and growth rate were significantly higher than that before the treatment,but HtSDSBA was significantly lower than that before the treatment (P ＜ 0.05).After the treatment,the uterine volume was (1.37 ± 0.47) cm3 and the ovarian volume was (1.12 ± 0.46) cm3,which were significantly lower than those before the treatment (P ＜ 0.05).After the treatment,the highest concentration of luteinizing hormone was (1.57 ± 0.67) U/L and the highest concentration of follicle stimulating hormone was (3.52 ± 0.81) mU/ml,which were significantly lower than those before the treatment (P ＜ 0.05).Conclusions Gonadotropin-releasing hormone analog in combination with growth hormone in the treatment of girls with post-menarche idiopathic central precocious puberty can improve the patient's predicted adult height and worth being clinically generalized.
